Health

Cancer

Overview

Our cancer research area combines the activities of multidisciplinary research teams with the aim of improving outcomes for cancer patients.

We operate a strong collaborative research model where molecular and cellular biologists work alongside bioinformaticians, medicinal chemists, surgeons, oncologists and industrial partners to provide a real bench-to-bedside approach to tackling this disease.

Research programs

  • Prostate cancer
  • Breast cancer
  • Ovarian cancer
  • Endometrial cancer
  • Lung cancer
  • Melanoma

Infrastructure

Performance

Evidence of research quality

ERA (Excellence in Research for Australia) 2015 score:

  • 4 (above world standard) -
    • Oncology and Carcinogenesis (FOR 1112).

ERA (Excellence in Research for Australia) evaluates the quality of research undertaken in Australian universities against national and international benchmarks.

Developing new researchers

Research students
32
Early career researchers
18

Publication output

2011

Unique count
Total
67
High quality
42%
Author weighting
Total
15
High quality
47%

Research income

2011 total
$4,833,197 (funding split)
2007-2011
$17,064,636 (funding split)

Key grants

  • Australian Prostate Cancer Research Centre - Queensland (APCRC-Q) - Australian Government
  • Smart Futures Premier's Fellowship (Professor Colleen Nelson)
  • Australian-Canadian Prostate Cancer Research Alliance - National and International Research Alliances Program (NIRAP)
  • Australian Prostate Cancer Collaboration (APCC) Bio-Resource - National Health and Medical Research Council (NHMRC)

Partnerships

International linkages

  • Canada
  • Ireland
  • USA
  • Hong Kong
  • UK
  • New Zealand

Cross-disciplinary engagement

  • Biology
  • Biochemistry
  • Genomics
  • Bioinformatics
  • Clinical sciences
  • Medical physics
  • Public health
  • Cancer health services

Impact

Evidence of impact

  • Establishment of the multidisciplinary team clinic for advanced prostate cancer
  • Establishment of a Prostate Cancer Clinical Trials Unit at Princess Alexandra Hospital
  • Identification of prognostic biomarkers
  • Therapeutic development programs targeting gene targets including kallikreins, ID2, Daxx, YB-1, GADD45G, Ghrelin, EphB4, PAR2, tocotrienol and CDCP1
  • ihop Program – Improving Health Outcomes for People
  • Novel therapeutic approaches
  • Improved understanding of cancer biology

Research enquiries

IHBI research enquiries

Contact us to find out about research and discovery at the Institute of Health and Biomedical Innovation (IHBI).